AbbVie admits $46bn attempt to acquire Shire
This article was originally published in Scrip
Executive Summary
AbbVie has made three different bids to acquire Dublin-based Shire, the most recent of which valued the Irish specialty pharmaceutical company at £46.26 per share, or about £27bn ($46bn), which is a 23.8% premium to Shire's 19 June closing price of £37.38 on the London Stock Exchange.